Information Bulletin

Ministry of Health, NSW
73 Miller Street North Sydney NSW 2060
Locked Mail Bag 961 North Sydney NSW 2059
Telephone (02) 9391 9000 Fax (02) 9391 9101
http://www.health.nsw.gov.au/policies/

Tenecteplase Replacement In Public Hospitals for Ambulance Paramedics

Document Number	IB2013_063
Publication date	10-Dec-2013
Functional Sub group	Clinical/ Patient Services - Critical care Clinical/ Patient Services - Pharmaceutical
Summary	Describes the process and requirments for replacement of Tenecteplase used by ambulance paramedics as part of the Pre-Hospital Thrombolysis (PHT) program.
Author Branch	Agency for Clinical Innovation
Branch contact	Agency for Clinical Innovation 02 9464 4620
Applies to	Local Health Districts, NSW Ambulance Service, Public Hospitals
Audience	Directors of Pharmacy, Emergency Department Medical and Nursing Staff
Distributed to	Public Health System, Ministry of Health
Review date	10-Dec-2018
Policy Manual	Patient Matters
File No.	
Status	Active

Director-General

INFORMATION BULLETIN

TENECTEPLASE REPLACEMENT IN PUBLIC HOSPITALS FOR NSW AMBULANCE PARAMEDICS

PURPOSE

This Information Bulletin is to provide guidance on tenecteplase replacement in public hospitals for NSW Ambulance Paramedics.

KEY INFORMATION

The Pre-Hospital Thrombolysis (PHT) program is part of the State Cardiac Reperfusion Strategy (SCRS) that is being progressively implemented by the Local Health Districts (LHD) with support from the Agency for Clinical Innovation (ACI) in collaboration with NSW Ambulance.

As part of the PHT program, NSW Ambulance paramedics administer intravenous tenecteplase to eligible patients with ST Elevation Myocardial Infarction (STEMI) prior to the patient arriving at the hospital.

In accordance with an Authority issued under the Poisons and Therapeutic Goods Regulation 2008 (NSW), a registered nurse in charge (or his/her delegate) of the Emergency Department (ED) of a public hospital that receives a patient following pre-hospital administration of thrombolytic therapy, is permitted to supply a NSW Ambulance paramedic with one vial of tenecteplase 50mg from ED stock, at the time of patient handover (i.e. 1:1 replacement) to restock the Ambulance Medication kit.

A record of the supply of tenecteplase from the ED, signed and dated by the nurse in charge of the ED (or his/her delegate) and the NSW Ambulance paramedic, must be kept for accountability over the movement of prescription medicines and audit purposes.

The replacement vial must be unused and in its original packaging and should have at least six (6) months shelf life prior to the expiry date.

Replacement should occur even if the hospital only holds one vial of tenecteplase 50mg in stock. In such cases, the Local Health District (LHD) and hospitals will determine how the hospital stock will be replaced according to their local pharmaceutical supply policies.

Processes to facilitate the replacement of tenecteplase provided to paramedics by the ED will be established locally.

In most cases, the patient receiving the pre-hospital tenecteplase would have received tenecteplase at that hospital if the PHT program was not in place (or at another hospital within the same LHD).

These replacement arrangements apply only to tenecteplase that has been used for a patient. Expired stock will not be replaced, nor will any other medication used by paramedics.

The procurement, storage, recording, handling and supply of tenecteplase by a hospital must be in accordance with the NSW Ministry of Health Policy Directive PD2013_043 Medication Handling in NSW Public Health Facilities.